China NMPA Drug Inspection - Sichuan Gukang Pharmaceutical Co., Ltd. - Sichuan Shegan

On November 13, 2020, the Chongqing Municipal Drug Administration announced that 12 batches of drugs from 11 manufacturers failed to meet national quality standards. Affected companies include Hebei Chufeng Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Shengshi Jinrong Pharmaceutical Co., Ltd., Shanxi Fenhe Pharmaceutical Co., Ltd., and several others specializing in traditional Chinese medicine. The inspections, conducted by various regional testing institutes, found that products like Isatis Root, Cassia Seed, and Vitamin U Belladonna Aluminum Capsules did not comply with the Chinese Pharmacopoeia 2015 Edition. The main violations included failures in content determination (active ingredient levels), incorrect botanical identification, and substandard physical properties, such as moldy samples and improper appearance. In response, the Chongqing Municipal Drug Administration has ordered the immediate sealing, seizure, and recall of all non-compliant products. Sales of these batches must be suspended, and the companies involved face formal investigations to ensure compliance with drug safety laws. Notably, several manufacturers have denied producing the specific batches identified in the report, suggesting potential supply chain issues.